IL295014B1 - A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma - Google Patents

A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma

Info

Publication number
IL295014B1
IL295014B1 IL295014A IL29501422A IL295014B1 IL 295014 B1 IL295014 B1 IL 295014B1 IL 295014 A IL295014 A IL 295014A IL 29501422 A IL29501422 A IL 29501422A IL 295014 B1 IL295014 B1 IL 295014B1
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
angiolipoma
acid
weight
dosage
Prior art date
Application number
IL295014A
Other languages
English (en)
Hebrew (he)
Other versions
IL295014A (en
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Publication of IL295014A publication Critical patent/IL295014A/en
Publication of IL295014B1 publication Critical patent/IL295014B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
IL295014A 2020-01-28 2021-01-27 A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma IL295014B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062966577P 2020-01-28 2020-01-28
PCT/IB2021/000035 WO2021152390A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Publications (2)

Publication Number Publication Date
IL295014A IL295014A (en) 2022-09-01
IL295014B1 true IL295014B1 (en) 2026-05-01

Family

ID=77078612

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295014A IL295014B1 (en) 2020-01-28 2021-01-27 A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma

Country Status (7)

Country Link
US (1) US20230089484A1 (cg-RX-API-DMAC10.html)
EP (1) EP4096653A4 (cg-RX-API-DMAC10.html)
JP (1) JP7850665B2 (cg-RX-API-DMAC10.html)
CN (1) CN115335047B (cg-RX-API-DMAC10.html)
AU (1) AU2021213469B2 (cg-RX-API-DMAC10.html)
IL (1) IL295014B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021152390A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4031130A4 (en) * 2019-09-15 2023-10-11 Raziel Therapeutics Ltd. COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS
US20240335424A1 (en) * 2021-07-28 2024-10-10 Raziel Therapeutics Ltd. Compositions and methods for treating lipoma pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
WO2015061280A1 (en) * 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
WO2015061280A1 (en) * 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIAL NCT04229030 (PHASE 2B)., RZL-012 FOR DERCUM'S DISEASE LIPOMAS, 14 January 2020 (2020-01-14) *
SHIN YS, ET AL., SONOGRAPHIC DIFFERENTIATION BETWEEN ANGIOLIPOMAS AND SUPERFICIAL LIPOMAS, 30 November 2016 (2016-11-30) *

Also Published As

Publication number Publication date
CN115335047B (zh) 2025-09-19
CN115335047A (zh) 2022-11-11
JP7850665B2 (ja) 2026-04-23
AU2021213469B2 (en) 2026-06-04
IL295014A (en) 2022-09-01
EP4096653A1 (en) 2022-12-07
AU2021213469A1 (en) 2022-08-25
WO2021152390A1 (en) 2021-08-05
EP4096653A4 (en) 2024-02-28
US20230089484A1 (en) 2023-03-23
JP2023510865A (ja) 2023-03-15

Similar Documents

Publication Publication Date Title
KR102375262B9 (en) GLP-1 Pharmaceutical composition comprising sustained release-microsphere comprising GLP-1 Analogue or pharmaceutically acceptable salt thereof
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
FI4054719T3 (fi) Ras-estäjiä
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
RU2016141570A (ru) Комбинации ингибитора fgfr и ингибитора igf1r
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
PL3829628T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
AR038618A1 (es) Forma poliformica cristalina de clorhidratos de irinotecan
PL4277628T3 (pl) Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego
CA3264923A1 (en) COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE
MX2021005944A (es) Inhibidores de rip1.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
PH12019502767A1 (en) Oral pharmaceutical formulations of remogliflozin
KR102467285B9 (ko) 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물
MX2016009226A (es) Combinaciones farmaceuticas.
NZ593282A (en) Ethanamine compounds and their use for treating depression
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.
IL306116A (en) New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them
ZA202200331B (en) Naltrexone formulation
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti